Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram in Obsessive-compulsive Disorder
NCT00215137Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2004
- Primary completion
- Jan 2009
- Countries
- 1
- Sponsor
- Duke University
- Modality
- Small Molecules
- Drugs
- escitalopram
- Conditions
- obsessive compulsive disorder (OCD)
01
Overview
Phase 2, randomised, double-blind trial of escitalopram in obsessive compulsive disorder (OCD) (3 arms), sponsored by Duke University. Primary endpoint: Yale Brown Obsessive Compulsive Scale at Week 8. Started Oct 2004; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Open Label Escitalopram
Daily escitalopram 10-20 mg
Placebo
Placebo comparator
Escitalopram
Continued escitalopram 20 mg
03
Who it enrols
Patients with OCD and a YBOCS score >= 16, excluding those with other primary psychiatric disorders, substance abuse, or prior failure of citalopram/escitalopram.
04
Endpoints
Primary
Yale Brown Obsessive Compulsive Scale
05
Results
Primary endpoints met
Beyond the preview
Go deeper on NCT00215137.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215137.